# Larry Hsu

> Larry Hsu, PhD, is the founder and CEO of AmMax Bio and a pharmaceutical company builder whose career spans product development at Abbott, the co-founding and scaling of Nasdaq-listed Impax Laboratories, and a return to early-stage biotechnology through LifeMax and AmMax. His current work centers on assembling oncology programs from clinically informed components, partnerships, and a deliberately compact operating team.

- **Role:** Founder and Chief Executive Officer at AmMax Bio
- **Organizations:** AmMax Bio, LifeMax Laboratories, Impax Laboratories, Abbott Laboratories, AiViva, Hercules Bio-Venture Partners, Capital Ten II Fund
- **Education:** PhD in Pharmaceutics, University of Michigan, BS in Pharmacy, National Taiwan University
- **Known for:** Co-founded Impax and helped build it into a Nasdaq-listed specialty pharmaceutical company with more than 1,000 employees., Led Impax partnerships with companies including Teva, AstraZeneca, Pfizer, and Shire., Received the University of Michigan College of Pharmacy's 2015 Alumni Distinguished Lifetime Achievement Award.

## Career timeline

- **c. 1980-1995** — Worked for 15 years at Abbott, ultimately serving as Director of Product Development with worldwide responsibilities spanning development, process engineering, clinical supplies manufacturing, and production technical support.
- **1995** — Co-founded Impax Pharmaceuticals, later known as Impax Laboratories.
- **1999** — Impax went public through a reverse acquisition of Global Pharmaceuticals and adopted the Impax Laboratories name.
- **2006** — Added the Chief Executive Officer role at Impax while continuing as president.
- **2014** — Retired from Impax in April after the company had grown beyond 1,000 employees and reached a market capitalization reported near $3 billion.
- **2014** — Started LifeMax Laboratories to focus on new drug development and served as its chairman and CEO.
- **2015** — Received the University of Michigan College of Pharmacy Alumni Distinguished Lifetime Achievement Award.
- **2015** — Began serving as a board member of AiViva.
- **2020** — Founded AmMax Bio in partnership with Amgen, initially around an exclusive worldwide license to a clinical-stage antibody asset.
- **2024** — AmMax and MD Anderson announced licensing and clinical-trial agreements for AMB-066.
- **2025** — AmMax announced that the first patient had been dosed in its Phase 2a AMB-066 study at MD Anderson.
- **2026** — AmMax licensed ADC technologies from Lonza for AMB-104 and appointed Travis Read as president and COO.

## Achievements

- Co-founded Impax and helped build it into a Nasdaq-listed specialty pharmaceutical company with more than 1,000 employees.
- Led Impax partnerships with companies including Teva, AstraZeneca, Pfizer, and Shire.
- Received the University of Michigan College of Pharmacy's 2015 Alumni Distinguished Lifetime Achievement Award.
- Authored papers and book chapters in natural-products and formulation fields and was named on pharmaceutical dosage-form patents.
- Founded AmMax Bio in 2020 through a partnership with Amgen.

## Latest updates

- **2026-06** — AmMax appointed Travis Read as president and chief operating officer; Hsu said Read would help guide capital formation, portfolio strategy, and operational execution.
- **2026-06** — AmMax licensed Lonza ADC technologies for AMB-104 and said it planned an IND submission in early 2027.
- **2025-01** — AmMax announced the first patient dosed in its Phase 2a study of AMB-066 at MD Anderson.
- **2024-12** — AmMax and MD Anderson announced worldwide license and clinical-trial agreements for AMB-066.

## Links

- Website: https://www.ammaxbio.com/
- LinkedIn: https://www.linkedin.com/in/larry-hsu-b42a9677

---

Profile page: https://yespress.io/larry-hsu
Published by YesPress — https://yespress.io
Last updated: 2026-08-18